期刊文献+

阿托伐他汀钙知识产权保护策略分析 被引量:2

Analysis of Atorvastatin Calcium Intellectual Property Protection Strategy
下载PDF
导出
摘要 通过查阅阿托伐他汀钙知识产权保护的相关中英文文献,分析药品知识产权保护相关法律法规以及药品阿托伐他汀钙知识产权保护策略,以期为国内药品企业如何合理延长专利药保护期,获得企业利润最大化提供借鉴意义。 Access to the relevant literature of atorvastatin calcium intellectual property protection in Chinese and English, we analyze drug-related intellectual property protection laws and regulations and the intellectual property strategies which implemented by Pfizer to protect the drug atorvastatin calcium, in order to provide reference how to domestic drug companies for a reasonable extension of patent protection on drugs, and promote the maximization of corporate profits.
出处 《中国药物评价》 2014年第6期362-365,369,共5页 Chinese Journal of Drug Evaluation
关键词 阿托伐他汀钙 知识产权 专利 Atorvastatin calcium Intellectual property Patent
  • 相关文献

参考文献16

二级参考文献35

  • 1杨莉,李野,岳晨妍.美国的药品数据保护及启示[J].中国药房,2007,18(10):730-733. 被引量:16
  • 2杨莉,李野.浅析药品专利期延长制度[J].中国新药杂志,2007,16(12):905-908. 被引量:16
  • 3HARRIS G. Prilosec's maker switches users to nexium[ J]. Thwar- ting Generics, WALL ST. J. ,2002,13 ( 6 ) :23 - 24.
  • 4Pub. L. No. 97-414. The Orphan Drug Act[ S]. Amended the Fed- eral Food, Drug and Cosmetic Act ( FFDCA ) as of January, 4, 1983.
  • 5EUREK SE. Hath-Waxman reform and accelerated market entry of generic drug: is faster necessarily better[ J]. Duke L Tech Rev, 2003,22(16) :18 - 19.
  • 6FDA,the best pharmaceuticals for Children Act [EB/OL],http://www.fda.gov/opacom/laws/pharmkids/contents.html, 2002-01-04
  • 7Congressional budget office. How increased competition from generic drugs has affected prices and retures in the pharmaceutical industry[EB/OL] ,http://www.cbo.org/show.doc, 1998-07-15
  • 8Wendy H.Schacht, John R.Thomas, Patent law and its application to the pharmaceutical industry[EB/OL],http://www.ipmall.info/hosted-resources/crs/RL30756-0501 10.pdf,2005-01-10
  • 9Robin J. Strongin, Hatch-Waxman, Generics, and Patents: Balancing Prescription Drug Innovation, Competition, and Affordability[R],NATIONAL HEALTH POLICY FORUM Background Paper, Jun. 21,2002, 10
  • 10Frequently Asked Questions on the Patent Term Restoration Program[EB/OL], http://www.fda.gov/cder/about/smallbiz/pat ent-term.htm, 2005-07-22

共引文献91

同被引文献17

  • 1陈向东,张晨.在华制药领域专利技术资源竞争——美国制药企业专利资源竞争比较及其启示[J].中国软科学,2006(5):63-72. 被引量:17
  • 2阿托伐他汀案(CN 96195564. 3 ) [ S]. 2009.
  • 3来那度胺案(CN97180299.8)[S].2009.
  • 4辉瑞诺华施贵宝三巨头公布2014年研发费用.总额超过200亿美元[EB/OL]. (2015 -01 -28) [2016 -01 -11]. http://news, bioon. com/article/6665348. html.
  • 5中国《专利审查指南》(2010)第二部分第二章2.2.6[S].2010.
  • 6中国《专利审査指南》(2010)第二部分第十章3.4[S].2010.
  • 7Childrens hospital medical center corporation. Treating angiogen-esis esp. ocular neovasculariation-using teratogenic cpd.,pref.thalidomide or deriv.,e. g. for treating diabetic retinopathy ormacular degeneration: WO ,9480085Al [ P]. 1994 -09 - 15.
  • 8中国《专利审査指南》(1993)第二部分第十章4.1[S]. 1993.
  • 92010年美国值得关注的5大知识产权案[EB/OL]. [2016 -01 - 11 ]. http://ip. people, com. cn/GB/10773661 . html.
  • 10刘伯宁.未来新药研发何去何从[J].中国医药科学,2011,1(5):10-10. 被引量:4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部